Home
Live Updates
Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase the Remaining Royalties Payable to Phoenixus AG for SLS-002 (Intranasal Racemic Ketamine Program), All Future Success and... : comparemela.com
Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase the Remaining Royalties Payable to Phoenixus AG for SLS-002 (Intranasal Racemic Ketamine Program), All Future Success and...
NEW YORK, April 11, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the devel...
Related Keywords
New York ,
United States ,
Raj Mehra ,
Mike Moyer ,
Anthony Marciano ,
Michael Golembiewski ,
Javelin Pharmaceuticals Inc Hospira ,
Prnewswire Seelos Therapeutics Inc ,
Lifesci Advisors ,
Seelos Therapeutics Inc ,
Vyera Pharmaceuticals Ag ,
Nasdaq ,
Exchange Commission ,
Agency For Healthcare Research ,
Vyera Pharmaceuticals ,
Purchase Agreement ,
Acute Suicidal Ideation ,
Major Depressive Disorder ,
Post Traumatic Stress ,
Javelin Pharmaceuticals ,
Healthcare Research ,
Post Traumatic Stress Disorder ,
Private Securities Litigation Reform Act ,
Annual Report ,
Quarterly Reports ,
Sci Advisors ,
comparemela.com © 2020. All Rights Reserved.